Description:
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination
with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors
Title
- Brief Title: First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
- Official Title: A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.
Clinical Trial IDs
- ORG STUDY ID:
D9950C00001
- SECONDARY ID:
2019-004539-22
- SECONDARY ID:
04504669
- NCT ID:
NCT04504669
Conditions
- Clear Cell Renal Cell Cancer
- Non-Small-Cell Lung Cancer
- Triple Negative Breast Neoplasms
- Squamous Cell Cancer of Head and Neck
- Small Cell Lung Cancer
- Gastric Cancer
- Melanoma
- Cervical Cancer
- Advanced Solid Tumours
Interventions
Drug | Synonyms | Arms |
---|
AZD8701 | | Combination Therapy |
Durvalumab | MEDI4736 | Combination Therapy |
Purpose
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination
with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors
Detailed Description
This is a Phase I, First in Human, multicentre, open-label, multiple arm study with dose
escalations and expansions at selected doses. Dose-escalation will occur with AZD8701 in
monotherapy (Part 1) and in combination with durvalumab (Part 3) in selected participants
with HNSCC, TNBC, NSCLC, ccRCC, gastric cancer, melanoma, cervical cancer, small-cell lung
cancer and/or participants with solid tumours who have demonstrated a response to prior
PD-(L)1 treatment.
Disease specific expansions will occur with a selected dose AZD8701 in participants with
NSCLC (Part 2) and with a selected dose of AZD8701 and durvalumab in participants with TNBC
and clear cell RCC (Part 4).
Trial Arms
Name | Type | Description | Interventions |
---|
Monotherapy | Experimental | Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years. | |
Combination Therapy | Experimental | Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years. | |
Eligibility Criteria
Inclusion Criteria:
The study is comprised of 2 main parts Monotherapy (AZD8701) and Combined Therapy (AZD8701
and Durvalumab).
Inclusion criteria Dose escalation stages:
- Histological or cytological confirmation of a solid, malignant tumour including HNSCC,
TNBC, NSCLC, ccRCC, gastric cancer, melanoma, cervical cancer, SCLC, and/or
participants with other solid tumours who have demonstrated a response to prior
anti-PD-(L)1 treatment
- Participant with progressive disease that is refractory to standard therapies or for
which no standard therapies exist and a clinical trial is the best option for next
treatment based on prior response and/or tolerability to standard of care
Inclusion Criteria Dose Expansions:
Non Small Lung Cancer Participants who have received prior PD(L)1 treatment. Clear Cell
Renal Cancer Participants who have not received prior PD(L)1 treatment.
Triple negative Breast Cancer participants who have who have not received prior PD(L)1
treatment.
General inclusion criteria:
- Must be 18 year old at the time of screening
- Body weight > 35 kg
- Male and Female participants of childbearing potential must use effective methods of
contraception
- Capable of giving signed informed consent
- ECOG performance status of 0 to 1
- A serum albumin > 35g/L
- Life expectancy of > 12 weeks
- At least 1 lesion, that qualifies as a RECIST 1.1 target lesion at baseline. Tumour
assessment by CT scan or MRI must be performed within 28 days prior to treatment.
- Participants must provide a new or previous tumour sample
- Adequate organ system functions
Exclusion Criteria:
- A condition that, in the opinion of the Investigator, would interfere with evaluation
of the study intervention or interpretation of participant safety or study results
- History of allogeneic organ transplantation.
- Active or prior documented autoimmune or inflammatory disorders Uncontrolled
intercurrent illness
- Significant cardiac disease
- History of another primary malignancy except for
1. Malignancy treated with curative intent and with no known active disease ≥ 5
years
2. non-melanoma skin cancer
3. Adequately treated carcinoma in situ without evidence of disease.
- Participant with previous or confirmed Covid 19 diagnosis requiring significant
medical intervention
- Current clinical signs and symptoms consistent with COVID-19 or confirmed current
infection by appropriate laboratory test within the last 4 weeks prior to screening
- Any major unresolved toxicity from previous anticancer therapy
- Known allergy or hypersensitivity to any of the study interventions or any of the
study intervention excipients.
Prior/Concomitant Therapy
- Receipt of the last dose of anticancer therapy within 5 half-lives or ≤ 21 days prior
to the first dose of study
- Prior treatment with potential Treg depletion therapies including agents targeting
CTLA-4 for 90 days prior to enrolment on study.
- Participants who have received prior anti-PD-1, anti-PD-L1, or anti-CTLA-4:
1. Must not have experienced a toxicity that led to permanent discontinuation of
prior immunotherapy.
2. All AEs while receiving prior immunotherapy must have completely resolved or
resolved to baseline
3. Must not have experienced a ≥ Grade 3 imAE or a neurologic or ocular imAE of any
grade while receiving prior immunotherapy.
4. Must not have required the use of additional immunosuppression other than
corticosteroids for the management of an AE
- Current or prior use of immunosuppressive medication within 14 days before the first
dose of study drug. b. The following are exceptions to this criterion:
1. Intranasal, inhaled, topical steroids, or local steroid injections (eg,
intra-articular injection).
2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
prednisone or its equivalent
3. Steroids as premedication for hypersensitivity reactions (eg, CT scan
premedication)
- Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy
for cancer treatment
- Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of
radiation within 4 weeks of the first dose of study intervention.
- Major surgical procedure within 28 days prior to the first dose
- Participants receiving anticoagulation treatment for venous or arterial indications
- Participation in another clinical study with study intervention administered in the
last 30 days
- Female participants who are pregnant or breastfeeding or male and female participants
of reproductive potential who are not willing to employ effective birth control
Maximum Eligible Age: | 101 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of AEs and SAEs |
Time Frame: | From screening until 105 days after last dose of study treatment |
Safety Issue: | |
Description: | Determined according to Incidence and treatment related AEs and SAEs |
Secondary Outcome Measures
Measure: | Progression-free survival according to RECIST 1.1 by investigator assessment |
Time Frame: | every 8 weeks (first 48 weeks) and then every 12 weeks from start of treatment until the earlier of progression, death or end of study (for max 42 months) |
Safety Issue: | |
Description: | Time from start of study treatment to the date of objective disease progression or death (by any cause in the absence of progression) |
Measure: | Duration of Response according to RECIST 1.1 by investigator assessment |
Time Frame: | every 8 weeks (first 48 weeks) and then every 12 weeks from start of treatment until the earlier of progression, death or end of study (for max 42 months) |
Safety Issue: | |
Description: | Time from first documented response (that is subsequently confirmed) to the date of objective disease progression or death (by any cause in the absence of progression) |
Measure: | Disease Control Rate at 16 weeks according to RECIST 1.1 by investigator assessment |
Time Frame: | Every 8 weeks (first 48 weeks) and then every 12 weeks from start of treatment until the earlier of progression, death or end of study (for max 42 months) |
Safety Issue: | |
Description: | The proportion of subjects with a best response of CR or PR in first 16 weeks or SD for at least 16 weeks |
Measure: | Time to Response according to RECIST 1.1 by investigator assessment |
Time Frame: | Every 8 weeks (first 48 weeks) and then every 12 weeks from start of treatment until the earlier of progression, death or end of study (for max 42 months) |
Safety Issue: | |
Description: | Time from the start of study treatment until the date of first documented response (which is subsequently confirmed) |
Measure: | Best percentage change in tumour size according to RECIST 1.1 by investigator assessment |
Time Frame: | Every 8 weeks (first 48 weeks) and then every 12 weeks from start of treatment until the earlier of progression, death, start of subsequent anti-cancer therapy or end of study (for max 42 months) |
Safety Issue: | |
Description: | Best percentage change from baseline in sum of the diameters of target lesions |
Measure: | Overall Survival at 18 months |
Time Frame: | From start of treatment to earlier of death or end of study (for max 42 months) |
Safety Issue: | |
Description: | Time from start of treatment until death from any cause. |
Measure: | Plasma AZD8701 and associated PK parameters when administered as monotherapy and in combination with Durvalumab |
Time Frame: | From around 2 hours before start of first AZD8701 infusion until 105 days after last dose |
Safety Issue: | |
Description: | Data following the single and multiple-dose parts of the study will be analysed through NCA to determine Cmax |
Measure: | Plasma and urine concentrations of AZD8701 and associated PK parameters when administered as monotherapy and in combination with Durvalumab |
Time Frame: | From around 2 hours before start of first AZD8701 infusion until 105 days after last dose |
Safety Issue: | |
Description: | Data following the single and multiple-dose parts of the study will be analysed through NCA to determine tmax |
Measure: | Plasma and urine concentrations of AZD8701 and associated PK parameters when administered as monotherapy and in combination with Durvalumab |
Time Frame: | From around 2 hours before start of first AZD8701 infusion until 105 days after last dose |
Safety Issue: | |
Description: | Data following the single and multiple-dose parts of the study will be analysed through NCA to determine AUC |
Measure: | Urine concentrations of AZD8701 to assess renal clearance when administered as monotherapy and in combination with Durvalumab |
Time Frame: | From around 2 hours before start of first AZD8701 infusion to day 50 |
Safety Issue: | |
Description: | Urine samples will be collected to assess urine concentrations of AZD8701 at a series of timepoints to derive renal clearance |
Measure: | Serum concentrations of Durvalumab and associated PK parameters when administered in combination with AZD8701 |
Time Frame: | From before start of first infusion of Durvalumab until 105 days after last dose |
Safety Issue: | |
Description: | The following and other PK parameters may be reported as data allow: Cmax on Cycle 4 Day 1 (end of infusion concentration) and Cmin on Cycle 4 Day 1 (pre-dose concentration). |
Measure: | Change in FOXP3 mRNA expression |
Time Frame: | From day 1 to day 29 |
Safety Issue: | |
Description: | Percentage change in FOXP3 mRNA expression from pre-treatment (baseline) to post treatment |
Details
Phase: | Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | AstraZeneca |
Trial Keywords
- Solid Tumours
- Durvalumab
- MEDI4736
- AZD8701
- Non Small cell Lung cancer
- ccRenal Cancer
- TNBC
- first time in human
- PD-L1
- T regulatory cells
- FOXP3
Last Updated
August 16, 2021